Zhengye Biotechnology narrows net loss 13.3% as revenue falls 18.3%
JILIN — November 12, 2026 -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) narrowed its net loss by 13.3% to RMB22.2 million (US$3.3 million) in the six months ended June 30, 2026, even as net revenue fell 18.3% to RMB50.9 million from RMB62.3 million. The improvement came from cost cuts, not sales: operating expenses dropped 22.2% to RMB37.6 million, while cash fell to RMB31.9 million from RMB50.3 million at December 31, 2025.
Swine vaccines bring in 75% of revenue and roughly all gross profit
Swine vaccines generated RMB38.2 million of revenue, down 18.2% from RMB46.7 million and equal to 75% of the group total by FairsOnline's calculation. At a gross margin of 44.3%, against 45.9% a year earlier, swine alone works out to about RMB16.9 million of gross profit. That is slightly more than the group's reported RMB16.7 million, because poultry vaccines still run at a negative 2.9% margin.